Hospital or health organisation · founded 1956
Inova Health System
Falls Church, United States · inova.org
- Citations, last 5 years
- 36.8k
- Works, last 5 years
- 2 199
- h-index
- 259
- Scientists listed
- 0
- Grants since 2016
- 31
Grants received
2025–2030 · research · R01
Phenotyping Net Immune State with MicroRNAs in Cardiac Transplantation
Palak Shah · Inova Health System · funded by National Institutes of Health
2025–2026 · research · R13
From Lab to Labor: Advancing Diabetes Pregnancy Care
Sarah Crimmins · Inova Health System · funded by National Institutes of Health
2023–2025 · research · R21
The Scientific Value of Premature Infant Biospecimens Collection
Stephanie Prescott · Inova Health System · funded by National Institutes of Health
2023–2028 · research · R01
OPTIMUM OB-TXA: Optimal TIMing, route and dose of tranexamic acid prior to UMbilical cord clamp for postpartum hemorrhage prevention
Homa Khorrami Ahmadzia · Inova Health System · funded by National Institutes of Health
2023–2024 · research · R13
Defining Research and Care in Diabetes in Pregnancy
Scott A Sullivan · Inova Health System · funded by National Institutes of Health
2023–2028 · research · R01
OPTIMUM OB-TXA: Optimal TIMing, route and dose of tranexamic acid prior to UMbilical cord clamp for postpartum hemorrhage prevention
Homa Khorrami Ahmadzia · Inova Health System · funded by National Institutes of Health
2023–2028 · research · R01
OPTIMUM OB-TXA: Optimal TIMing, route and dose of tranexamic acid prior to UMbilical cord clamp for postpartum hemorrhage prevention
Homa Khorrami Ahmadzia · Inova Health System · funded by National Institutes of Health
2020–2025 · career development · K23
MicroRNA Biomarkers of Allograft Rejection and Cardiac Allograft Vasculopathy in Cardiac Transplantation
Palak Shah · Inova Health System · funded by National Institutes of Health
2020–2024 · research · R01
The optimal loop diuretic: mechanistic insights from longitudinal changes in blood and urine proteins to explain efficacy and safety of torsemide vs furosemide after a heart failure hospitalization
Lauren Beth Cooper · Inova Health System · funded by National Institutes of Health
2020–2025 · career development · K23
Frailty and Resiliency in Older Adults with Acute Myocardial Infarction
Abdulla Al Damluji · Inova Health System · funded by National Institutes of Health
2020–2025 · career development · K23
Frailty and Resiliency in Older Adults with Acute Myocardial Infarction
Abdulla Al Damluji · Inova Health System · funded by National Institutes of Health
2020–2024 · research · R01
The optimal loop diuretic: mechanistic insights from longitudinal changes in blood and urine proteins to explain efficacy and safety of torsemide vs furosemide after a heart failure hospitalization
Lauren Beth Cooper · Inova Health System · funded by National Institutes of Health
2020–2025 · career development · K23
Frailty and Resiliency in Older Adults with Acute Myocardial Infarction
Abdulla Al Damluji · Inova Health System · funded by National Institutes of Health
2020–2025 · research · R01
The optimal loop diuretic: mechanistic insights from longitudinal changes in blood and urine proteins to explain efficacy and safety of torsemide vs furosemide after a heart failure hospitalization
Lauren Beth Cooper · Inova Health System · funded by National Institutes of Health
2020–2025 · career development · K23
MicroRNA Biomarkers of Allograft Rejection and Cardiac Allograft Vasculopathy in Cardiac Transplantation
Palak Shah · Inova Health System · funded by National Institutes of Health
2020–2026 · career development · K23
Frailty and Resiliency in Older Adults with Acute Myocardial Infarction
Abdulla Al Damluji · Inova Health System · funded by National Institutes of Health
2020–2024 · research · R01
The optimal loop diuretic: mechanistic insights from longitudinal changes in blood and urine proteins to explain efficacy and safety of torsemide vs furosemide after a heart failure hospitalization
Lauren Beth Cooper · Inova Health System · funded by National Institutes of Health
2020–2025 · career development · K23
MicroRNA Biomarkers of Allograft Rejection and Cardiac Allograft Vasculopathy in Cardiac Transplantation
Palak Shah · Inova Health System · funded by National Institutes of Health
2020–2025 · research · R18
The Heart Failure Collaboratory Public-Private Partnership Between the United States Food and Drug Administration, the Inova Heart and Vascular Institute, and the Heart Failure Community
Christopher M O'Connor · Inova Health System · funded by U.S. Food and Drug Administration
2020–2025 · career development · K23
Frailty and Resiliency in Older Adults with Acute Myocardial Infarction
Abdulla Al Damluji · Inova Health System · funded by National Institutes of Health
2020–2025 · career development · K23
MicroRNA Biomarkers of Allograft Rejection and Cardiac Allograft Vasculopathy in Cardiac Transplantation
Palak Shah · Inova Health System · funded by National Institutes of Health
2020–2025 · career development · K23
MicroRNA Biomarkers of Allograft Rejection and Cardiac Allograft Vasculopathy in Cardiac Transplantation
Palak Shah · Inova Health System · funded by National Institutes of Health
2020–2026 · research · R18
The Heart Failure Collaboratory Public-Private Partnership Between the United States Food and Drug Administration, the Inova Heart and Vascular Institute, and the Heart Failure Community
Christopher M O'Connor · Inova Health System · funded by U.S. Food and Drug Administration
2020–2025 · research · R18
The Heart Failure Collaboratory Public-Private Partnership Between the United States Food and Drug Administration, the Inova Heart and Vascular Institute, and the Heart Failure Community
Christopher M O'Connor · Inova Health System · funded by U.S. Food and Drug Administration
2019–2021 · career development · K23
The contribution of antibiotic exposure in the prenatal, peripartum and infancy period to intestinal microbiome perturbations and association with early childhood obesity.
Suchitra Hourigan · Inova Health System · funded by National Institutes of Health
2019–2024 · career development · K23
The contribution of antibiotic exposure in the prenatal, peripartum and infancy period to intestinal microbiome perturbations and association with early childhood obesity.
Suchitra Hourigan · Inova Health System · funded by National Institutes of Health
2019–2024 · career development · K23
The contribution of antibiotic exposure in the prenatal, peripartum and infancy period to intestinal microbiome perturbations and association with early childhood obesity.
Suchitra Hourigan · Inova Health System · funded by National Institutes of Health
2015–2021 · research · R01
Computational modeling of tumor burden by CT to advance cancer therapeutics
Rene Bruno · Inova Health System · funded by National Institutes of Health
2015–2021 · research · R01
Computational modeling of tumor burden by CT to advance cancer therapeutics
Rene Bruno · Inova Health System · funded by National Institutes of Health
2015–2021 · research · R01
Computational modeling of tumor burden by CT to advance cancer therapeutics
Rene Bruno · Inova Health System · funded by National Institutes of Health
2015–2022 · research · R01
Computational modeling of tumor burden by CT to advance cancer therapeutics
Rene Bruno · Inova Health System · funded by National Institutes of Health